drugset
drugset / Trial / NCT02603562

Evaluate Safety and Biological Activity of ATYR1940 in Participants With Early Onset Facioscapulohumeral Muscular Dystrophy

NCT02603562 ↗

Phase 1/2 Completed 8 enrolled aTyr Pharma, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and biological activity of ATYR1940 in participants with early onset FSHD.

Timeline

Start
2016-03-30
Primary completion
2016-12-12
Completion
2016-12-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ATYR1940 Unknown 3 mg/kg Intravenous

Indications

facioscapulohumeral muscular dystrophy